# Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

> **NCT00568750** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 47 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00568750
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-22
- **Primary completion:** 2012-01-18
- **Final completion:** 2018-05-16
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568750, "Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00568750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*